Effects of GF 109203X on P-glycoprotein-mediated multidrug resistance
Author Information
Author(s): V Gekeler, R Boer, F Uberall, W Ise, C Schubert, I Utz, J Hofmann, KH Sanders, C Schachtele, K Klemm, H Grunicke
Hypothesis
Inhibition of protein kinase C (PKC) is a new approach for overcoming multidrug resistance (MDR) in cancer chemotherapy.
Conclusion
The bisindolylmaleimide GF 109203X interacts directly with P-glycoprotein to influence multidrug resistance, but does not significantly affect PKC's role in this process.
Supporting Evidence
- The bisindolylmaleimide GF 109203X shows selective inhibition of PKC isozymes in vitro.
- GF 109203X did not produce any anti-proliferative activity at concentrations up to 10 µM.
- Direct interaction of GF 109203X with P-glycoprotein was demonstrated through binding competition experiments.
- PKC inhibition by GF 109203X was effective in the nanomolar concentration range.
Takeaway
This study shows that a specific drug can help cancer treatments work better by blocking a protein that makes cancer cells resistant to drugs.
Methodology
The study used various P-glycoprotein-overexpressing cell lines to evaluate the effects of GF 109203X on multidrug resistance through several assays.
Limitations
The study does not explore the phosphorylation of cellular targets under the influence of GF 109203X.
Want to read the original?
Access the complete publication on the publisher's website